Evaluation of New Biomarkers in Stage 3 and 4 Endometriosis

Bagcilar Training and Research Hospital

Status: Completed

Conditions: Endometriosis

Treatments: Procedure: other benign condition surgeries; Procedure: endometriosis surgery

Study type: Observational

Funder types: Other

Identifiers

NCT05312528

2018.01.1.01.001

Details and patient eligibility

About

The diagnostic value of Annexin V, sVCAM-1, sICAM-1, vascular endothelial growth factor and Proinflammatory cytokines (TNF-a and interleukin-6) in ovarian endometriosis and deep infiltrating endometriosis, their levels in organ-specific involvement, their relationship with symptoms, and the changes of these markers in the postoperative period will be evaluated.

Full description

Serum Annexin V, sVCAM-1, sICAM-1, vascular endothelial growth factor and proinflammatory cytokines (TNF-a and interleukin-6) values were studied by taking blood samples from all patients before and three months after the operation.

Enrollment: 79 patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Stage III and IV endometriosis patients requiring surgery due to chronic pelvic pain or suspected malignancy

Exclusion criteria

1. Malignant disease
2. Ovarian failure
3. Acute pelvic inflammatory disease
4. Smokers
5. Pregnancy
6. Chronic autoimmune disease

Trial design

79 participants in 2 patient groups

Study Group

Description:

Stage 3 and 4 endometriosis patients

Treatment:

Procedure: endometriosis surgery

Control Group

Description:

Patients without endometriosis, who required surgery for tubal ligation, benign ovarian cysts or uterine fibroids were included.

Treatment:

Procedure: other benign condition surgeries